使用联合分析法确定骨质疏松症医疗管理的患者偏好
该研究在学术医疗中心纳入304例骨质疏松症患者完成在线联合分析,量化6种药物属性的相对重要性。结果显示预防髋部骨折的疗效占决策31.0%,60.9%的患者将疗效列为选择治疗的首要因素,其余40%更看重其他因素,且患者特征不能可靠预测决策,作者认为需要开发共享决策工具。
要点
- 预防髋部骨折的疗效占决策权重31.0%,给药方式占17.5%,严重副作用风险占16.6%。
- 60.9%的患者在选择骨质疏松治疗时将药物疗效列为最优先因素。
- 大学学历、对用药必要性信念更强及从未使用过骨质疏松药物与优先考虑疗效相关。
核心结论
- 约60%的患者在选择骨质疏松治疗时优先考虑疗效,其余40%更看重其他因素。
- 患者个体特征和临床因素不能可靠预测患者决策,作者认为有必要开发和实施共享决策工具。
研究设计与样本
- 在学术医疗中心纳入骨质疏松症患者,完成在线联合分析练习,计算每例患者对6种骨质疏松药物属性的相对重要性评分(评分越高表示在决策中相对重要性越大)。
- 使用潜在类别分析识别具有相似选择模式的患者亚组,并使用逻辑回归判断人口学特征和骨质疏松疾病特征是否与潜在类别归属相关。
- 共304名参与者完成调查。
主要发现
- 药物属性按重要性评分排序为:预防髋部骨折的疗效(占决策31.0%)、给药方式(17.5%)、严重副作用风险(16.6%)、给药频率(13.9%)、预防脊柱骨折的疗效(12.5%)、非严重副作用风险(8.4%)。
- 60.9%的队列在选择治疗时将药物疗效列为最优先因素。
- 大学学历、对使用骨质疏松药物必要性信念更强以及从未使用过骨质疏松药物是唯一与在决策过程中优先考虑预防骨折疗效而非其他因素相关的因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We used conjoint analysis-a method that assesses complex decision making-to quantify patients' choices when selecting an osteoporosis therapy. While 60% of people prioritized medication efficacy when deciding among treatments, the remaining 40% highly valued factors other than efficacy, suggesting the need for personalized shared decision-making tools. INTRODUCTION: In this study, we aimed to examine patient decision-making surrounding osteoporosis medications using conjoint analysis. METHODS: We enrolled osteoporosis patients at an academic medical center to complete an online conjoint exercise which calculated each patient's relative importance score of 6 osteoporosis medication attributes (higher = greater relative importance in decision-making). We used latent class analysis to identify distinct segments of patients with similar choice patterns and then used logistic regression to determine if demographics and osteoporosis disease features were associated with latent class assignment. RESULTS: Overall, 304 participants completed the survey. The rank order of medication attributes by importance score was the following: efficacy at preventing hip fractures (accounted for 31.0% of decision making), mode of administration (17.5%); risk of serious side effects (16.6%); dose frequency (13.9%); efficacy at preventing spine fractures (12.5%); risk of non-serious side effects (8.4%). We found that 60.9% of the cohort prioritized medication efficacy as their top factor when selecting among the therapies. Being a college graduate, having stronger beliefs on the necessity of using medications for osteoporosis, and never having used osteoporosis medicines were the only factors associated with prioritizing medication efficacy for fracture prevention over the other factors in the decision-making process. CONCLUSIONS: While about 60% of patients prioritized efficacy when selecting an osteoporosis therapy, the remaining 40% valued other factors more highly. Furthermore, individual patient characteristics and clinical factors did not reliably predict patient decision making, suggesting that development and implementation of shared decision-making tools is warranted.
引用
- Liu X, Makaroff KE, Almario CV, et al. Determining patient preferences for the medical management of osteoporosis using conjoint analysis. Osteoporos Int. 2023. PMID: 37721558. doi:10.1007/s00198-023-06882-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。